全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

宫颈人乳头瘤病毒检测方法的研究进展
The Research Progress Laboratory Diagnostics Methods of Human Papillomavirus

DOI: 10.12677/ACM.2023.133514, PP. 3589-3595

Keywords: 人乳头瘤病毒,HPV检测,宫颈癌筛查,分子标志物,综述
Human Papillomavirus (HPV)
, HPV Detection, Cervical Cancer Screening, Molecular Markers, Review

Full-Text   Cite this paper   Add to My Lib

Abstract:

宫颈癌是女性群体的高发疾病之一,我国每年宫颈癌新发病例约10万例,是威胁女性健康的重大疾病。宫颈癌筛查是促进其早诊断早治疗的有效措施,基于细胞学的检测是以往筛查方案的基石,但近年来国内外均建议选择基于HPV的检测作为初级筛查的方案之一,随着对人乳头瘤病毒(HPV)检测方法的更新,各种检测方法的优缺点及适用范围均需得到进一步剖析,本文将对其进展展开研究与讨论。
Cervical cancer is one of the high-incidence diseases in the female population, and there are about 100,000 new cases of cervical cancer in China every year, which is a major disease that threatens women’s health. Cervical cancer screening is an effective measure to promote its early diagnosis and early treatment, cytology-based detection is the cornerstone of the previous screening program, but in recent years, it is recommended to choose HPV-based detection as one of the primary screening programs at home and abroad, with the update of the human papillomavirus (HPV) detection method, the advantages and disadvantages of various detection methods and the scope of applica-tion need to be further analyzed, this article will carry out research and discussion on its progress.

References

[1]  Lee, H., Choi, M., Jo, M., et al. (2020) Assessment of Clin-ical Performance of an Ultrasensitive Nanowire Assay for Detecting Human Papillomavirus DNA in Urine. Gynecologic Oncology, 156, 641-646.
https://doi.org/10.1016/j.ygyno.2019.11.031
[2]  Derbie, A., Mekonnen, D., Woldeamanuel, Y., et al. (2020) HPV E6/E7 mRNA Test for the Detection of High Grade Cervical Intraepithelial Neoplasia (CIN2+): A Systematic Review. Infectious Agents and Cancer, 15, 9.
https://doi.org/10.1186/s13027-020-0278-x
[3]  顾青, 赵艳. 子宫颈HPV E6、E7mRNA检测的临床诊断及预后评估价值研究进展[J]. 诊断学理论与实践, 2019, 18(2): 228-232.
[4]  Shi, W.J., Liu, H., Wu, D., et al. (2017) E6/E7 Proteins Are Potential Markers for the Screening and Diagnosis of Cervical Pre-Cancerous Lesions and Cervical Cancer in a Chinese Population. Oncology Letters, 14, 6251-6258.
https://doi.org/10.3892/ol.2017.6932
[5]  蒋杰, 毕玉晰, 李志茹, 等. 人乳头瘤病毒E6/E7在宫颈癌中的研究进展[J]. 临床误诊误治, 2018, 31(11): 101-105.
[6]  Daponte, A., Michail, G., Daponte, A.I., et al. (2021) Urine HPV in the Context of Genital and Cervical Cancer Screening-An Update of Current Literature. Cancers (Basel), 13, 1640.
https://doi.org/10.3390/cancers13071640
[7]  Aarnio, R., Isacson, I., Sanner, K., et al. (2021) Comparison of Vaginal Self-Sampling and Cervical Sampling by Medical Professionals for the Detection of HPV and CIN2+: A Randomized Study. International Journal of Cancer, 148, 3051-3059.
https://doi.org/10.1002/ijc.33482
[8]  Zhao, X.L., Xu, X.Q., Duan, X.Z., et al. (2020) Comparative Performance Evaluation of Different HPV Tests and Triaging Strategies Using Self-Samples and Feasibility Assessment of Thermal Ablation in “Colposcopy and Treat” Approach: A Population-Based Study in Rural China. International Journal of Cancer, 147, 1275-1285.
https://doi.org/10.1002/ijc.32881
[9]  王志强. 尿液人乳头瘤病毒检测在宫颈病变筛查中的应用前景[J]. 实用妇产科杂志, 2016, 32(2): 103-105.
[10]  刘晓旭, 梁建梅, 苏学艳, 等. HPV DNA和HPV E6/E7 mRNA检测在宫颈病变诊治中应用价值的比较[J]. 国际妇产科学杂志, 2021, 48(4): 462-466.
[11]  王侠. p16/Ki67和E6/E7 mRNA在宫颈癌筛查中的研究进展(综述) [J]. 安徽卫生职业技术学院学报, 2021, 20(3): 122-124.
[12]  Maver, P.J. and Poljak, M. (2020) Primary HPV-Based Cervical Cancer Screening in Europe: Implementation Status, Challenges, and Future Plans. Clinical Microbiology and Infection, 26, 579-583.
https://doi.org/10.1016/j.cmi.2019.09.006
[13]  杨文娟, 叶君, 陈炎, 等. HPV E6/E7 mRNA与HPV-23分型检测用于宫颈脱落细胞学阳性女性的临床价值[J]. 浙江医学, 2021, 43(14): 1509-1512.
[14]  Artaza-Irigaray, C., Molina-Pineda, A., Aguilar-Lemarroy, A., et al. (2019) E6/E7 and E6(*) from HPV16 and HPV18 Upregulate IL-6 Ex-pression Independently of p53 in Keratinocytes. Frontiers in Immunology, 10, 1676.
https://doi.org/10.3389/fimmu.2019.01676
[15]  魏丽惠, 李明珠, 王悦. 《世界卫生组织子宫颈癌癌前病变筛查和治疗指南(第2版)》解读[J]. 中国医学前沿杂志(电子版), 2021, 13(9): 44-48.
[16]  Arbyn, M., Simon, M., Peeters, E., et al. (2021) 2020 List of Human Papillomavirus Assays Suitable for Primary Cervical Cancer Screening. Clinical Microbiology and Infection, 27, 1083-1095.
https://doi.org/10.1016/j.cmi.2021.04.031
[17]  Bhatla, N. and Singhal, S. (2020) Primary HPV Screening for Cervical Cancer. Best Practice & Research Clinical Obstetrics & Gynae-cology, 65, 98-108.
https://doi.org/10.1016/j.bpobgyn.2020.02.008
[18]  Mongia, A., Pompeo, G., Sani, C., et al. (2021) Hybrid Capture 2 and cobas? 4800: Comparison of Performance of Two Clinically Validated Tests for Human Papillomavirus Primary Screening of Cervical Cancer. Journal of Medical Screening, 28, 472-479.
https://doi.org/10.1177/0969141321992820
[19]  Liao, Y. and Li, Q. (2019) Profile of MeltPro(R) HPV Test for Human Papillomavirus Genotyping and Cervical Precancer Screening. Expert Review of Molecular Diagnostics, 19, 857-862.
https://doi.org/10.1080/14737159.2019.1662299
[20]  Geraets, D.T., Cuschieri, K., De Koning, M.N., et al. (2014) Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control. Journal of Clinical Microbiology, 52, 3996-4002.
https://doi.org/10.1128/JCM.01962-14
[21]  Artaza-Irigaray, C., Flores-Miramontes, M.G., Olszewski, D., et al. (2019) Cross-Hybridization between HPV Genotypes in the Linear Array Genotyping Test Confirmed by Next-Generation Sequencing. Diagnostic Pathology, 14, 31.
https://doi.org/10.1186/s13000-019-0808-2
[22]  Zhao, G., Tian, Y., Du, Y., et al. (2019) Comparison of Cervi-HPV and Hybrid Capture 2 HPV Tests for Detection of High-Risk HPV Infection in Cervical Swab Specimens. Diag-nostic Cytopathology, 47, 439-444.
https://doi.org/10.1002/dc.24134
[23]  邹普润, 周卫华, 夏柳, 等. 宫颈癌早期筛查方法的研究进展[J]. 湖北民族大学学报(医学版), 2020, 37(4): 48-51.
[24]  Frayle, H., Gori, S., Rizzi, M., et al. (2019) HPV Testing for Cervi-cal Cancer Screening: Technical Improvement of Laboratory Logistics and Good Clinical Performance of the Cobas 6800 in Comparison to the 4800 System. BMC Women’s Health, 19, 47.
https://doi.org/10.1186/s12905-019-0743-0
[25]  Bottari, F. and Iacobone, A.D. (2019) Profile of the BD HPV OnclarityTM Assay. Expert Review of Molecular Diagnostics, 19, 565-570.
https://doi.org/10.1080/14737159.2019.1622415
[26]  厉瑶, 胡旻, 胡美旭, 等. HPV E6/E7 mRNA检测在宫颈高级别病变筛查中的应用分析[J]. 浙江临床医学, 2021, 23(3): 417-419.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133